Rossari Biotech Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Rossari Biotech Ltd trades at ₹531, in a downtrend and 81 weeks into that stage. That is −2.7% against its own 200-day average. It sits at 48% of a 52-week range of ₹398 to ₹675. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).

Today the stock is in a downtrend — week 81 of stage 4, confirmed. At ₹531 it trades −2.7% versus its 200-day average and sits at 48% of its 52-week range (₹398–₹675).

Against the market, two honest reads. Cumulative: over the last 6.0 years the stock moved −27% while the NIFTY 500 moved +157% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 5th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Rossari Biotech Ltd trades at 18.0× P/E, near the bottom of its own range — cheaper only 5% of the time. Its long-run median P/E is 37.0×, measured across 6.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 18.0× is near the bottom of its own range — cheaper only 5% of the time, against a long-run median of 37.0× measured over 6.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +9.4% against a −28.5% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −14.6%/yr price move, ~+11.9%/yr came from earnings growth and ~−26.5 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Rossari Biotech Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 16.7% and holding. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

60.4/100 — rank 2 of 3 in Seeds/Tissue Culture/Bio Technology · 97% evidence confidence

Rossari Biotech Ltd scores 60.4 out of 100 against the 3 companies it is compared with in Seeds/Tissue Culture/Bio Technology, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 20.4 + 12.8 + 12.7 + 14.5 = 60.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Rossari Biotech Ltd reported ₹697 Cr of revenue in the Jun 26 quarter, +28.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 7 years it has compounded at 24.5% a year. The last full year, FY26, came in at ₹2,396 Cr. The last four reported quarters add to ₹2,550 Cr.

Rossari Biotech Ltd reported ₹697 Cr of revenue in the Jun 26 quarter, +28.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 7 years it has compounded at 24.5% a year. The last full year, FY26, came in at ₹2,396 Cr. The last four reported quarters add to ₹2,550 Cr.

FY26 revenue came in at ₹2,396 Cr (+15.2% on the year), capping 7 years at 24.5% compound. The latest quarter (Jun 26) printed ₹697 Cr, +28.1% year on year — the 12th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +19.4% growth against the decade's 24.5% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +19.4% over the last 4 quarters against +15.5%/yr over the last 8 — accelerating; TTM profit +11.9% vs +5.4%/yr — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 12.0% this quarter (+0.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Rossari Biotech Ltd's operating margin is 12.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 12.0% to 17.0%. The current quarter sits inside that band.

Rossari Biotech Ltd's operating margin is 12.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 12.0% to 17.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 12.0%, +0.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 12.0%–17.0%.

🚨 Why the margin moved: operating margin went −0.9 pp year on year while gross margin went −2.1 pp — the loss came mostly from the gross line: input costs and pricing.

→ Margins held — did that reach the bottom line? Next: profit +2.9% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Rossari Biotech Ltd earned ₹35.0 Cr of net profit in the Jun 26 quarter, +2.9% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹149 Cr. The 7-year compound rate is 18.3%. That is 5.0% of the quarter's revenue. The same quarter a year earlier earned ₹34.0 Cr.

Rossari Biotech Ltd earned ₹35.0 Cr of net profit in the Jun 26 quarter, +2.9% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹149 Cr. The 7-year compound rate is 18.3%. That is 5.0% of the quarter's revenue. The same quarter a year earlier earned ₹34.0 Cr.

Jun 26 profit was ₹35.0 Cr, +2.9% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹149 Cr (+9.6%), and the 7-year compound rate is 18.3%.

Why profit moved: revenue contributed +28.1% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +11.7% vs revenue +19.4%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

→ Profit rose — but did the cash follow? Next: 59% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 59% of Rossari Biotech Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹65.0 Cr of operating cash against ₹149 Cr of profit. After ₹298 Cr of capital spending, ₹−233 Cr was left as free cash.

FY26: operating cash of ₹65.0 Cr against reported profit of ₹149 Cr, leaving free cash of ₹−233 Cr after ₹298 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 59% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at 59%: the cash cycle stretched 57 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 57 days — the next section's job is to find where the cash is stuck.

→ So follow the cash to where it goes. Next: the 103-day cycle, in money terms.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Rossari Biotech Ltd's cash conversion cycle runs 103 days in FY26, up from 46 days in FY21. Capital spending ran ₹562 Cr over the last 3 years. At FY26 sales of ₹2,396 Cr each day of that cycle holds about ₹6.6 Cr, so roughly ₹676 Cr sits inside the business at any moment.

FY26: debtors at 85 days, inventory at 88 days — roughly 2.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 103 days, looser than FY21's 46.

The full loop: cash goes out to suppliers and production on day 0; stock waits 88 days to sell; customers pay about 85 days after that; and suppliers themselves are paid at 71 days — netting out to the 103-day cycle.

In money terms: at FY26 sales of ₹2,396 Cr, each day of the cycle holds about ₹6.6 Cr — so the 103-day loop keeps roughly ₹676 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹562 Cr over the last 3 fiscal years against ₹206 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹173 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 13% and the ROIC − WACC spread is −3.3 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Rossari Biotech Ltd earns a ROCE of 13% in FY26. Return on invested capital clears the cost of that capital by −3.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 6.2% net margin on 1.05× asset turns.

FY26 ROCE is 13%.

🚨 Why the return is what it is — the wiring (FY26): 6.2% net margin × 1.05× asset turns × 1.71× balance-sheet leverage ≈ 11.1% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 8.7% − 12.0% = a −3.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.33.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Rossari Biotech Ltd carries total debt of ₹436 Cr against shareholder equity of ₹1,333 Cr as of Jun 26, a debt-to-equity of 0.33. On the annual view that ratio went from 0.01 in FY22 to 0.33 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of ₹436 Cr against shareholder equity of ₹1,333 Cr — a debt-to-equity of 0.33. On the annual view, debt-to-equity went from 0.01 (FY22) to 0.33 (FY26). Read the returns on this page with that leverage in mind.

→ Who owns this, and are they adding or leaving? Next: Domestic institutions cut 2.2 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions cut 2.2 points of Rossari Biotech Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 14.6% of the company. Foreign institutions moved −1.8 points over the same window, to 2.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: −2.2 points over 8 quarters to 14.6%; Foreign institutions: −1.8 points over 8 quarters to 2.0%; Promoters: −0.2 points over 8 quarters to 68.1%.

🚨 Why the register moved: domestic institutions drove it (−2.2 points), alongside foreign institutions (−1.8 points) — distribution into the market’s bid.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Rossari Biotech Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions